Sugi Predict

Sugi Predict / Compounds / SCHEMBL3339153

SCHEMBL3339153

SCHEMBL3339153

Cc1cc2nc(CSc3cccc(F)c3)cc(O)n2n1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 2/20 0.39
▸ MAOA P21397 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.37
▸ SMN1; SMN2 Q16637 4/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ CXCR2 P25025 1/20 0.37
▸ RECQL P46063 1/20 0.37
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ MAPT P10636 3/20 0.36
▸ L3MBTL1 Q9Y468 4/20 0.35
▸ LMNA P02545 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.34
▸ PDE10A Q9Y233 1/20 0.34
▸ HPGD P15428 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3344200 0.86 MAPT (0.43) MAOBMAOASMN1; SMN2MEN1KMT2A
SCHEMBL3338701 0.85 CXCR2 (0.40) MAOBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3339372 0.81 PTGDR2 (0.40) MAOBSMN1; SMN2MEN1KMT2ANPC1
SCHEMBL3341624 0.81 CXCR2 (0.50) MAOBCXCR2RAB9A
SCHEMBL3338499 0.80 CXCR2 (0.39) MAOBALDH1A1SMN1; SMN2KMT2ACXCR2
SCHEMBL3338709 0.75 KDM1A (0.38) MAOBMAOAALDH1A1SMN1; SMN2MEN1
SCHEMBL956581 0.71 CXCR2 (0.57) MAOBALDH1A1MEN1KMT2ACXCR2
SCHEMBL954380 0.70 RXFP1 (0.47) ALDH1A1SMN1; SMN2CXCR2MAPTL3MBTL1
SCHEMBL956425 0.70 KDM4E (0.39) MAOBALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL956573 0.69 FFAR1 (0.50) CXCR2RAB9AMAPTLMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 — — US claimed
EP-2094697-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS Novartis AG (CH) 2009-09-02 — — EP claimed
WO-2008062026-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS NOVARTIS AG (CH) 2008-05-29 — — WO claimed
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 — — US disclosed
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 — — US disclosed
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 — — US disclosed
EP-2094697-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A]PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS Novartis AG (CH) 2009-09-02 — — EP disclosed
WO-2008062026-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS NOVARTIS AG (CH) 2008-05-29 — — WO disclosed
WO-2008062026-A1 5-SULFANYLMETHYL-PYRAZOLO [1,5-A] PYRIMIDIN-7-OL DERIVATIVES AS CXCR2 ANTAGONISTS NOVARTIS AG (CH) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152205-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR3 MAOB 3882/4885MAOA 4538/4885ALDH1A1 931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.